147 related articles for article (PubMed ID: 35890074)
1. Pharmacogenetics of Metformin Transporters Suggests No Association with Therapeutic Inefficacy among Diabetes Type 2 Mexican Patients.
Ortega-Ayala A; Rodríguez-Rivera NS; Andrés F; LLerena A; Pérez-Silva E; Espinosa-Sánchez AG; Molina-Guarneros JA
Pharmaceuticals (Basel); 2022 Jun; 15(7):. PubMed ID: 35890074
[TBL] [Abstract][Full Text] [Related]
2. Impact of
Ortega-Ayala A; De Andrés F; Llerena A; Bartolo-Montiel CM; Molina-Guarneros JA
Biomed Rep; 2024 Aug; 21(2):117. PubMed ID: 38938740
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic Evaluation of Metformin and Sulphonylurea Response in Mexican Mestizos with Type 2 Diabetes.
Marta M; Sánchez-Pozos K; Jaimes-Santoyo J; Monroy-Escutia J; Rivera-Santiago C; de Los Ángeles Granados-Silvestre M; Ortiz-López MG
Curr Drug Metab; 2020; 21(4):291-300. PubMed ID: 32407269
[TBL] [Abstract][Full Text] [Related]
4. Frequency of
Cuautle-Rodríguez P; Rodríguez-Rivera N; De Andrés F; Castillo-Nájera F; Llerena A; Molina-Guarneros JA
Biomed Rep; 2019 May; 10(5):283-295. PubMed ID: 31086662
[TBL] [Abstract][Full Text] [Related]
5. Altered Glycemic Control Associated With Polymorphisms in the SLC22A1 (OCT1) Gene in a Mexican Population With Type 2 Diabetes Mellitus Treated With Metformin: A Cohort Study.
Reséndiz-Abarca CA; Flores-Alfaro E; Suárez-Sánchez F; Cruz M; Valladares-Salgado A; Del Carmen Alarcón-Romero L; Vázquez-Moreno MA; Wacher-Rodarte NA; Gómez-Zamudio JH
J Clin Pharmacol; 2019 Oct; 59(10):1384-1390. PubMed ID: 31012983
[TBL] [Abstract][Full Text] [Related]
6. Association of Met420del Variant of Metformin Transporter Gene SLC22A1 with Metformin Treatment Response in Ethiopian Patients with Type 2 Diabetes.
Degaga A; Sirgu S; Huri HZ; Sim MS; Kebede T; Tegene B; Loganadan NK; Engidawork E; Shibeshi W
Diabetes Metab Syndr Obes; 2023; 16():2523-2535. PubMed ID: 37641646
[TBL] [Abstract][Full Text] [Related]
7. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response.
Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
Pharmacogenet Genomics; 2010 Jan; 20(1):38-44. PubMed ID: 19898263
[TBL] [Abstract][Full Text] [Related]
8. Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients.
Umamaheswaran G; Praveen RG; Damodaran SE; Das AK; Adithan C
Clin Exp Med; 2015 Nov; 15(4):511-7. PubMed ID: 25492374
[TBL] [Abstract][Full Text] [Related]
9. rs622342 in
Naja K; Salami A; El Shamieh S; Fakhoury R
J Pers Med; 2020 Jun; 10(2):. PubMed ID: 32575674
[TBL] [Abstract][Full Text] [Related]
10. CYP2C9*3 gene variant contributes independently to glycaemic control in patients with type 2 diabetes treated with glibenclamide.
Castelán-Martínez OD; Hoyo-Vadillo C; Bazán-Soto TB; Cruz M; Tesoro-Cruz E; Valladares-Salgado A
J Clin Pharm Ther; 2018 Dec; 43(6):768-774. PubMed ID: 29802808
[TBL] [Abstract][Full Text] [Related]
11. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients.
Tarasova L; Kalnina I; Geldnere K; Bumbure A; Ritenberga R; Nikitina-Zake L; Fridmanis D; Vaivade I; Pirags V; Klovins J
Pharmacogenet Genomics; 2012 Sep; 22(9):659-66. PubMed ID: 22735389
[TBL] [Abstract][Full Text] [Related]
12. Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes.
Dujic T; Causevic A; Bego T; Malenica M; Velija-Asimi Z; Pearson ER; Semiz S
Diabet Med; 2016 Apr; 33(4):511-4. PubMed ID: 26605869
[TBL] [Abstract][Full Text] [Related]
13. Effect of Metformin on Glycemic Control Regarding Carriers of the
Zepeda-Carrillo EA; Ramos-Lopez O; Martínez-López E; Barrón-Cabrera E; Bernal-Pérez JA; Velasco-González LE; Rangel-Rios E; Bustamante Martínez JF; Torres-Valadez R
Diabetes Metab Syndr Obes; 2022; 15():1771-1784. PubMed ID: 35711690
[TBL] [Abstract][Full Text] [Related]
14. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
15. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin.
Shikata E; Yamamoto R; Takane H; Shigemasa C; Ikeda T; Otsubo K; Ieiri I
J Hum Genet; 2007; 52(2):117-122. PubMed ID: 17111267
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms potentially associated with response to metformin in postmenopausal diabetics suffering and not suffering with cancer.
Berstein LM; Iyevleva AG; Vasilyev D; Poroshina TE; Imyanitov EN
Cell Cycle; 2013 Dec; 12(23):3681-8. PubMed ID: 24145224
[TBL] [Abstract][Full Text] [Related]
17. Association of
Chen P; Cao Y; Chen S; Liu Z; Chen S; Guo Y
Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289808
[TBL] [Abstract][Full Text] [Related]
18. Association of the Reduced Function Met420del Polymorphism of SLC22A1 with Metformin-Induced Gastrointestinal Intolerance in Ethiopian Patients with Type 2 Diabetes Mellitus.
Degaga A; Sirgu S; Huri HZ; Sim MS; Loganadan NK; Kebede T; Tegene B; Engidawork E; Shibeshi W
Pharmgenomics Pers Med; 2024; 17():183-191. PubMed ID: 38715682
[TBL] [Abstract][Full Text] [Related]
19. Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09).
Joerger M; van Schaik RH; Becker ML; Hayoz S; Pollak M; Cathomas R; Winterhalder R; Gillessen S; Rothermundt C
Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):167-72. PubMed ID: 25753371
[TBL] [Abstract][Full Text] [Related]
20. The influence of
Ebid AIM; Ehab M; Ismail A; Soror S; Mahmoud MA
J Drug Assess; 2019; 8(1):115-121. PubMed ID: 31231590
[No Abstract] [Full Text] [Related]
[Next] [New Search]
